RxDoctor Payments DataLook up a doctor →

Joseph Stevenson, DO

Cardiovascular Disease · Reno, NVNPI 1467444901

Payments from drug & device makers

$362,771in general payments, 2019–2025

Across 824 payments — averaging $440.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Actelion Pharmaceuticals US, Inc.$90K
  • Janssen Research & Development, LLC$90K
  • United Therapeutics Corporation$59K
  • Actelion Pharmaceuticals, Ltd$45K
  • Boehringer Ingelheim$26K
  • Lilly USA, LLC$23K
  • plus $30K from 40 others

What the payments were for

  • Consulting fees$3,4202%
  • Speaking & faculty fees$181,82182%
  • Travel & lodging$15,8627%
  • Food & beverage$19,0349%
  • Education$2170%
  • Other$1,9021%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$362,771 in reported general payments places this provider in the 95th percentile of 165 cardiovascular disease providers in Nevada.

See all cardiovascular disease providers in Nevada

Medicare billing

Part B allowed, 2024
$528,007
Medicare patients
924
Services billed
3,402

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OpsumitMacitentan316$3,964,108
AdempasRiociguat227$3,088,907
Tyvaso DpiTreprostinil68$1,615,837
UptraviSelexipag60$1,365,782
Orenitram ErTreprostinil Diolamine69$1,031,570
EliquisApixaban392$468,365
Ambrisentan155$341,767
Tadalafil309$296,543
OpsynviMacitentan/Tadalafil21$266,234
JardianceEmpagliflozin200$241,973
XareltoRivaroxaban111$167,855
EntrestoSacubitril/Valsartan72$110,042
Repatha SureclickEvolocumab142$109,517
RemodulinTreprostinil Sodium20$73,744
Praluent PenAlirocumab66$36,336

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi, Opsynvi$90,382$5,596,125397 claims
BayerAdempas$650$3,088,907227 claims
PfizerEliquis$611$468,365392 claims
Boehringer IngelheimJardiance$26,279$241,973200 claims
Johnson & JohnsonXarelto$1,085$167,855111 claims
NovartisEntresto$1,120$110,04272 claims
United Therapeutics CorporationRemodulin$58,770$73,74420 claims
Lilly USA, LLCMounjaro$23,123$30,25421 claims
AstraZenecaFarxiga$657$24,07624 claims
Esperion Therapeutics, Inc.Nexlizet$367$13,01514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 165 cardiovascular disease providers in Nevada.

Other cardiovascular disease in Reno

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →